Colivelin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Colivelin 是一种神经保护肽和 STAT3 激活剂。 Colivelin 是一种混合肽，旨在增强护脑素 (HN) 的神经保护作用。

Colivelin is a neuroprotective peptide and activator of STAT3. Colivelin is a hybrid peptide synthesized to enhance the neuroprotective effects of humanin (HN).Colivelin is a hybrid peptide composed of ADNF and AGA-(C8R)HNG17, a potent Humanin (HN) derivative. Humanin (HN) and its derivatives, such as Colivelin (CLN), suppress neuronal death induced by insults related to Alzheimer's disease (AD) by activating STAT3. Colivelin completely suppresses death induced by overexpressed FAD-causative genes and A 1-43 at a concentration of 100 fM, whereas AGA-(C8R)HNG17 does so at a concentration of 10 pM.Humanin (HN) and its derivatives, such as Colivelin (CLN) also ameliorate functional memory impairment of mice induced by anticholinergic drugs or soluble toxic amyloid-β (Aβ) Intracerebroventricular administration of Colivelin not only completely suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, but also it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42.

Colivelin completely suppresses death induced by overexpressed FAD-causative genes and Aβ1-43 at a concentration of 100 fm, and keep its neuroprotective action at or above the levels of 1 nm.Colivelin-induced neuroprotection occurs via two neuroprotective pathways: one mediated by Ca2+/calmodulin-dependent protein kinase IV, triggered by ADNF, and one mediated by signal transducer and activator of transcription 3, triggered by HN.Colivelin reverses caspase3, Bax and Bcl-2 expressions in HT22 cells medaited by rmMFG-E8 in the co-cultured cells under OGD condition.Colivelin (50 μg/mL, 4 hours) significantly increases the p-STAT3 protein levels in BV-2 cells. Western Blot Analysis Cell Line:BV-2 cells.Concentration:50 μg/mL.Incubation Time:4 hours.Result:Increased p-STAT3 levels.Cell Viability Assay Cell Line:KYSE70 and TE8 cells.Concentration:0.5 μM.Incubation Time:1 hour (followed by CYT-Rx20 treatment) Result:Sgnificantly suppressed the viability in KYSE70 and TE8 cells.

Colivelin (intracerebroventricular administration; 10 pmol/3 μl; 3 weeks) suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, in addition, it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42.Colivelin (intraperitoneal administration; 1.4, 7, or 35 nM/0.21 mL; on the Y-maze testday) suppresses memory impairment caused by3-quinuclidinyl benzilateand restricts functional memory deficit.Colivelin (intraperitoneal injection; 1 mg/kg; 14 days) results in improved motor and cognitive function with time by performance of mNSS, rotarod, and corner turning test.It also reduces lesion volume and improves neurological deficits after MCAO. Animal Model:CD-1 mice Dosage:10 pmol/3 μl Administration:Intracerebroventricular administrationResult:Completely suppressed Aβ 25-35-mediated impairment in spatial working memory and increased the number of immunoreactive neurons. Animal Model:C57 mice Dosage:1.4, 7, or 35 nM/0.21mL Administration:Intraperitoneal administration Result:Protected against cholinotoxin-induced amnesia in mice.Animal Model: Male C57BL/6 mice Dosage:1 mg/kg Administration:Intraperitoneal administration Result:Protected against ischemic brain injury, and improves neurological outcomes

——

JAK/STAT Signaling

STAT

STAT3|Amyloid-β

——

——

867021-83-8

2645.1

C119H206N32O35

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (37.81 mM)

——

——

(-20℃)

With Ice Pack

≥ 2 years